Glomerular Hyperfiltration in Adult Sickle Cell Anemia: a Frequent Hemolysis Associated Feature
Overview
Authors
Affiliations
Background And Objectives: Sickle cell anemia-associated nephropathy is a growing matter of concern because renal failure affects most aging sickle cell anemia patients. Glomerular damage is a common feature revealed by a microalbuminuria or a macroalbuminuria. Although glomerular hyperfiltration has been described for decades in this population, its prevalence in young adults is unknown.
Design, Setting, Participants, & Measurements: To address this issue, as well as the clinical and biologic correlates of hyperfiltration, a single-center, cross-sectional study of 280 homozygous SS disease patients was performed.
Results: The prevalence of hyperfiltration assessed by Modification of Diet in Renal Disease estimated GFR was 51%. Among patients with hyperfiltration, 49% had hyperfiltration alone, whereas 36% and 15% had an associated microalbuminuria or macroalbuminuria, respectively. Estimated GFR sensitivity and specificity for hyperfiltration were 94% and 63%, respectively, in a selected subgroup of 48 patients (measured GFR was assessed by urinary (51)Cr EDTA clearance). In patients with no albuminuria, hyperfiltration status was significantly associated with a young age (years), the absence of alpha thalassemia, a lower hemoglobin level (g/dl), and a lower fetal hemoglobin. The role of chronic hemolysis was further strengthened by multivariate analysis showing a correlation between estimated GFR and a low plasma fetal hemoglobin level, a young age, and a high reticulocyte count (r(2) = 0.54).
Conclusions: Together, the data suggest that the pathophysiology of hyperfiltration would rather be attributable to the hemolysis-associated vasculopathy rather than a viscosity-vaso-occlusive process.
Holub M, Lebeaux D, Grohs P, Joseph L, Pellerin O, Cheminet G Eur J Clin Microbiol Infect Dis. 2025; .
PMID: 39894862 DOI: 10.1007/s10096-024-05035-y.
Therapeutics for sickle cell disease intravascular hemolysis.
Xue J, Li X Front Physiol. 2024; 15:1474569.
PMID: 39345787 PMC: 11427376. DOI: 10.3389/fphys.2024.1474569.
Engole Mompango Y, Bukabau Busanga J, Makulo Rissassy J, Nlandu Mayamba Y, Makanzu B, Nkodila A Ren Fail. 2024; 46(2):2407888.
PMID: 39329176 PMC: 11441020. DOI: 10.1080/0886022X.2024.2407888.
Grujcic M, Milovanovic M, Nedeljkovic J, Jovanovic D, Arsenijevic D, Solovjova N Int J Mol Sci. 2024; 25(15).
PMID: 39125698 PMC: 11311984. DOI: 10.3390/ijms25158129.
Sickle Cell Disease and CKD: An Update.
Zahr R, Saraf S Am J Nephrol. 2023; 55(1):56-71.
PMID: 37899028 PMC: 10872505. DOI: 10.1159/000534865.